Physician profile
Sam S Abraham
NPI 1831349448
$23,143.84
in general payments reported to CMS, 2019-2025
77 companies · $4,071 in 2025
The $4,071 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,936 · 2020: $2,188 · 2021: $5,209 · 2022: $2,786 · 2023: $3,670 · 2024: $3,283 · 2025: $4,071.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Consulting Fee: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,849.27 |
| Consulting Fee | $175.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $3,820.63 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $1,965.26 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $1,818.25 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Amgen INC. | $1,745.32 | 2019-2025 | Evenity, Repatha, Prolia |
| Biohaven Pharmaceuticals, INC. | $1,513.15 | 2020-2021 | |
| Lilly USA, LLC | $1,332.02 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $1,212.25 | 2021-2025 | |
| Glaxosmithkline, LLC. | $916.25 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Abbott Laboratories | $815.75 | 2019-2025 | Freestyle Libre 3 |
| Pfizer INC. | $558.94 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $430.06 | 2019-2023 | |
| Astellas Pharma US INC | $385.26 | 2019-2025 | Veozah |
| Janssen Pharmaceuticals, INC | $344.08 | 2019-2025 | Spravato, Xarelto |
| Eisai INC. | $332.63 | 2020-2025 | |
| Allergan, INC. | $326.83 | 2019-2020 |
Show all 77 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sam Abraham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.